Context Therapeutics is trading at $0.27, up 12.22%, with the catalyst uncertain.
- No verified company-specific announcement explaining the October 16 move was found; the cited CT-202 dosing announcement predates this session.
- Broader market indexes and the supplied biotech-sector context are lower, so they do not clearly explain the gain.